1. Home
  2. IFS vs IMVT Comparison

IFS vs IMVT Comparison

Compare IFS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercorp Financial Services Inc.

IFS

Intercorp Financial Services Inc.

HOLD

Current Price

$46.43

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$23.60

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFS
IMVT
Founded
1897
2018
Country
Peru
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.0B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
IFS
IMVT
Price
$46.43
$23.60
Analyst Decision
Buy
Buy
Analyst Count
1
9
Target Price
$48.00
$30.78
AVG Volume (30 Days)
224.2K
916.9K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
2.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.38
N/A
P/E Ratio
$9.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.09
$12.72
52 Week High
$52.58
$29.25

Technical Indicators

Market Signals
Indicator
IFS
IMVT
Relative Strength Index (RSI) 47.27 32.65
Support Level $38.93 $21.74
Resistance Level $52.00 $24.63
Average True Range (ATR) 1.64 1.07
MACD -0.08 -0.33
Stochastic Oscillator 52.68 1.68

Price Performance

Historical Comparison
IFS
IMVT

About IFS Intercorp Financial Services Inc.

Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: